RHOH and neoplasm: Treatment of tumour-grafted animals with a tTF-NG2 antibody fusion protein have shown that tTF can be delivered to the tumour vasculature, can activate coagulation within the microvasculature and inhibit tumour growth (Brand et al., 2016).